ArticleActa diabetologica2021
Risk of cause-specific death, its sex and age differences, and life expectancy in post-pancreatitis diabetes mellitus.
Article in Acta diabetologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 23 citations in OpenAlex.
- An interpretable radiomics model based on contrast‑enhanced pancreatic computed tomography for predicting the prognosis of post-acute pancreatitis diabetes mellitus.BMC medical imaging · 2026Article
- Glucose-lowering therapy in diabetes of the exocrine pancreas: a real-world evidence analysis in a tertiary hospital in the timeframe 2018-2022.Therapeutic advances in endocrinology and metabolism · 2026Article
- Individualized prediction of post-acute pancreatitis diabetes mellitus by combining lipid metabolism and anatomical features.Insights into imaging · 2025Article
- A radiomics model of contrast-enhanced computed tomography for predicting post-acute pancreatitis diabetes mellitus.Quantitative imaging in medicine and surgery · 2024Article
- Mechanism exploration and biomarker identification of glycemic deterioration in patients with diseases of the exocrine pancreas.Scientific reports · 2024Article
- Article
- Machine learning for post-acute pancreatitis diabetes mellitus prediction and personalized treatment recommendations.Scientific reports · 2023Article
- Development of a Clinical Prediction Model for Diabetes in Chronic Pancreatitis: The PREDICT3c Study.Diabetes care · 2023Article
- Post-pancreatitis diabetes mellitus: insight on optimal management with nutrition and lifestyle approaches.Annals of medicine · 2022Review
- Pancreatic and gut hormones as predictors of new-onset prediabetes after non-necrotising acute pancreatitis: a prospective longitudinal cohort study.Endocrine connections · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
aimsThe aim was to investigate sex- and age-stratified risks of cause-specific death and life expectancy in individuals with post-pancreatitis diabetes mellitus (PPDM).
methodsNationwide data on mortality in New Zealand were obtained. For two head-to-head comparisons (PPDM versus type 2 diabetes mellitus [T2DM]; PPDM versus type 1 diabetes mellitus [T1DM]), the groups were matched on age, sex, and calendar year of diabetes diagnosis. Multivariable Cox regression analyses were conducted to estimate risks of vascular, cancer, and non-vascular non-cancer mortality. Remaining life expectancy at age of diabetes diagnosis was estimated using the Chiang II method.
resultsA total of 15,848 individuals (1,132 PPDM, 3,396 T1DM, and 11,320 T2DM) were included. The risks of vascular mortality and non-vascular non-cancer mortality did not differ significantly between PPDM and T2DM or T1DM. PPDM was associated with a significantly higher risk of cancer mortality compared with T2DM (adjusted hazard ratio, 1.32; 95% confidence interval, 1.08-1.63) or T1DM (adjusted hazard ratio, 1.65; 95% confidence interval, 1.27-2.13). The risk of cancer mortality associated with PPDM (versus T2DM) was significantly higher in women than in men (p for interaction = 0.003). This sex difference in cancer mortality risk was also significant in the comparison between PPDM and T1DM (p for interaction = 0.006). Adults of both sexes with PPDM had the lowest remaining life expectancy (in comparison with T2DM or T1DM) up to 64 years of age.
conclusionsPeople with PPDM have a higher risk of cancer mortality compared with those with T2DM or T1DM. This is especially pronounced in women. Young and middle-aged adults with PPDM have a lower life expectancy compared with their counterparts with T2DM or T1DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.